Entries by primitus

Engitix Therapeutics strengthens management team with new directors for fibrosis and computational biology

Company is on expansion curve with two new appointments and recent move to larger facilities London, UK – 23 Feb, 2021 – Engitix Ltd (‘Engitix’), a biotechnology company developing a portfolio of programmes in fibrosis and solid tumours and with two significant partnerships based on its pioneering proprietary human extracellular matrix (ECM) drug discovery platform, today […]

Engitix Therapeutics to relocate headquarters to new life sciences cluster, White City Place

London, UK – December 15, 2020 – Engitix Ltd (‘Engitix’), a biotechnology company with a portfolio of programmes in fibrosis and solid tumours and two significant partnerships based on its proprietary human extracellular matrix (ECM) platform, today announced that it is relocating its headquarters and operations to WestWorks, White City Place (WCP). The move follows […]

Engitix Appoints Eduardo Bravo as Chairman of its Board of Directors

London, UK – December 1, 2020 – Engitix Ltd (‘Engitix’), a biotechnology company with a portfolio of programmes in fibrosis and solid tumours and two significant partnerships based upon its proprietary human extracellular matrix (ECM) platform, today announced the appointment of Eduardo Bravo as Chairman of its Board of Directors. Eduardo has over 25 years […]

Engitix Signs Collaboration and Licensing Agreement with Takeda to Develop Anti-Fibrotic Therapies in Advanced Liver Diseases

Collaboration combines Engitix’s unique ECM platform with Takeda’s expertise in gastroenterology research and development (R&D) and commercialisation London, UK – 25 August 2020 – Engitix Ltd (‘Engitix’), a biotechnology company developing a portfolio of programmes in fibrosis and solid tumours using its proprietary human extracellular matrix (ECM) platform, today entered into a licensing and collaboration agreement […]

LSX World Congress

4-5 February 2020 LSX World Congress London, UK Team members attending: Dr Giuseppe Mazza, CEO [panel speaker]

Cirrhotic Human Liver Extracellular Matrix 3D Scaffolds Promote Smad-Dependent TGF-β1 Epithelial Mesenchymal Transition

January 2020 Cirrhotic Human Liver Extracellular Matrix 3D Scaffolds Promote Smad-Dependent TGF-β1 Epithelial Mesenchymal Transition Mazza. G, Telese. A, Al-Akkad. W, Frenguelli. L, Levi. A, Marrali. M, Longato. L, Thanapirom. K, Vilia. M.G, Lombardi. B, Crowley. C, Crawford. M, Karsdal. M.A, Leeming. D.J, Marrone. G, Bottcher. K, Robinson. B, Del Rio Hernandez. A, Tamburrino. D, […]

Engitix and Morphic Enter Research Collaboration to Identify ECM-related Targets in Fibrostenotic Inflammatory Bowel Disease (IBD)

London, UK and Waltham, Massachusetts, USA – 10 December, 2019 – Engitix Ltd (‘Engitix’), a biotechnology company developing a portfolio of programmes in fibrosis and solid tumours using its proprietary human extracellular matrix (ECM) platform, and Morphic Therapeutic (‘Morphic’), a biopharmaceutical company developing oral integrin therapies, today announce that they have entered into a research […]